Brachytherapy for cancer of the female urethra

Primary carcinomas of the female urethra are extremely rare, with an annual incidence of less than ten in one million. Currently, there is no consensus regarding management of this malignancy. However, there have been several case reports demonstrating the efficacy of chemoradiation in the treatment of female urethral cancer. In this report we present two cases of female primary urethral adenocarcinoma that were treated by concomitant chemotherapy and external beam radiotherapy, followed by interstitial brachytherapy.

show abstract

“…Radiotherapy and chemotherapy have been advocated in combination with surgery to improve treatment outcomes. 2–15 …”

Section: Introductionmentioning

confidence: 99%

Non-surgical treatment of primary female urethral cancer

2010

View full text Add to dashboard Cite

show abstract

“…Even though urethral cancer might have different biological behavior as compared to female PUC, experience of brachytherapy for treatment of urethral cancer might be helpful [13,14]. One of the largest series was reported by Milosevic et al [14].…”

Section: Discussionmentioning

confidence: 99%

High-dose-rate interstitial brachytherapy for female peri-urethral cancer

Sharma¹,

Gandhi²,

Bhatla

et al. 2016

jcb

View full text Add to dashboard Cite

Purpose: Peri-urethral cancer (PUC) in females is a rare malignancy. Surgery is not usually contemplated due to associated morbidity. Radiation therapy (RT) can be employed in the form of interstitial brachytherapy (IBT) alone for early lesions, and external beam radiation therapy (EBRT) with or without IBT for advanced lesions. We report our first experience in the literature to evaluate the role of high-dose-rate (HDR) IBT in female PUC.Material and methods: Between 2008 and 2013, 10 female patients with PUC (5 primary and 5 recurrent) were treated with HDR-IBT with or without EBRT at our center. Size of the lesion ranged from 1.5 cm to 5.0 cm. A 2-3 plane free-hand implant was performed using plastic catheters. The prescribed dose of HDR-IBT was 42 Gy in 14 fractions for brachytherapy alone (5 patients), and 18-21 Gy for the boost along with EBRT (5 patients). Patients were followed up regularly for assessment of disease control and toxicity.Results: At a median follow up of 25 months, six patients were disease free at their last follow up. Four patients developed recurrence: 2 at inguinal nodes, 1 at local site, and 1 at both local as well as inguinal nodes. Moist desquamation was the commonest acute toxicity observed in all 5 patients treated with IBT alone, which healed within 4 weeks' time. Overall, grade II delayed complication rate was 30%.Conclusions: Though small sample size, the results of our study have shown that HDR-IBT provides good loco-regional control with acceptable toxicity for female PUC.

show abstract

“…Primary urethral cancer presents with symptoms such as dysuria and later hematuria or regular bleeding. Due to the female anatomy, women have an increased risk for a late diagnosis [3, 4]. …”

Section: Purposementioning

confidence: 99%

“…The surgical approach depends on tumor stage and anatomic location and often results in major surgery with a pelvic exenteration [5]. Radiotherapy is an alternative to surgery and include external beam radiotherapy (EBRT), brachytherapy alone, or a combination of the two modalities [4, 6, 7]. …”

Section: Purposementioning

confidence: 99%

Successful treatment of a 67-year-old woman with urethral adenocarcinoma with the use of external beam radiotherapy and image guided adaptive interstitial brachytherapy

Mujkanovic¹,

Tanderup²,

Agerbæk³

et al. 2016

jcb

View full text Add to dashboard Cite

Primary urethral cancer (PUC) is a very rare disease. This case report illustrates a successful treatment approach of a 67-year-old woman with a urethral adenocarcinoma selected for an organ preserving treatment with external beam radiotherapy (EBRT) and interstitial brachytherapy (BT) boost, using the GEC-ESTRO target concept originally designed for locally advanced cervical cancer (LACC). Treatment included EBRT with 45 Gy in 25 fractions followed by image guided adaptive interstitial BT (IGABT) with a pulsed-dose-rate (PDR) BT boost with 30 Gy in 50 hourly pulses. The D90 for CTVHR was 79.1 Gy in EQD23. At 24 months follow-up, the patient was recurrence free and without treatment related side effects.

show abstract

Brachytherapy for cancer of the female urethra

Cited by 24 publications

References 26 publications

Non-surgical treatment of primary female urethral cancer

Non-surgical treatment of primary female urethral cancer

High-dose-rate interstitial brachytherapy for female peri-urethral cancer

Successful treatment of a 67-year-old woman with urethral adenocarcinoma with the use of external beam radiotherapy and image guided adaptive interstitial brachytherapy

Contact Info

Product

Resources

About